317 studies found for:    biogen | biogen
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Recruiting A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: BG00012 (dimethyl fumarate) - Reference form;   Drug: BG00012 (dimethyl fumarate) - Test form
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Recruiting BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: BIIB023;   Biological: Placebo;   Drug: Mycophenolate Mofetil;   Drug: Oral corticosteroid regimen
6 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
7 Recruiting A Study Evaluating the Effectiveness of Tecfidera™ (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate (DMF)
8 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
9 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
10 Recruiting BIIB017 Related Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: Peginterferon beta-1a;   Drug: naproxen
11 Completed Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: BG00002
12 Completed Natalizumab (BG00002, Tysabi) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
Interventions: Drug: Natalizumab;   Drug: Placebo
13 Completed JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
14 Active, not recruiting Extension Study to Evaluate Safety and Efficacy of BG00002 (Natalizumab) in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
15 Active, not recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Interventions: Biological: BIIB033;   Drug: Placebo
16 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
17 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
18 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
19 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
20 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years